Wellness Center USA (WCUI) 10-K 8 Feb 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2020	Mar. 31, 2020
Cover [Abstract]
Entity Registrant Name	Wellness Center USA, Inc.
Entity Central Index Key	0001516887
Document Type	10-K
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float		$ 3,698,561
Entity Common Stock, Shares Outstanding	118,252,077
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2020	Sep. 30, 2019
Current Assets
Cash	$ 51,320	$ 53,147
Inventories	94,560
Prepaid expenses and other current assets	500	55,000
Total Current Assets	146,380	108,147
Property and equipment, net		1,562
Right of use asset	6,961
Total Other Assets	6,961	1,562
TOTAL ASSETS	153,341	109,709
Current Liabilities
Accounts payable and accrued expenses	408,297	457,037
Payroll taxes payable	92,334	102,834
Lease liability	6,961
Lease abandonment liability	672,878	234,582
Loans payable from officers and shareholders, including $369,250 past due at September 30, 2020	1,165,250	399,250
Total Current Liabilities	2,345,720	1,193,703
Long-term Liabilities
U.S. Small Businessss Administration PPP loan payable	37,166
Total Liabilities	2,382,886	1,193,703
Shareholders' Deficit
Common stock, par value $0.001, 200,000,000 shares authorized; 118,252,077 and 107,497,077 shares issued and outstanding, respectively	118,252	107,497
Additional paid-in capital	25,053,616	23,777,647
Accumulated deficit	(27,583,363)	(25,362,287)
Total Wellness Center USA shareholders' deficit	(2,411,495)	(1,477,143)
Non-controlling interest	181,950	393,149
Total Shareholder's deficit	(2,229,545)	(1,083,994)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$ 153,341	$ 109,709

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2020	Sep. 30, 2019
Statement of Financial Position [Abstract]
Loans payable from officers and shareholders, past due amount	$ 369,250
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares, issued	118,252,077	107,497,077
Common stock, shares, outstanding	118,252,077	107,497,077

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Sales:
Total Sales	$ 5,000	$ 33,375
Cost of goods sold		20,025
Gross profit	5,000	13,350
Operating expenses	1,926,594	1,779,934
Loss from operations	(1,921,594)	(1,766,584)
Other income (expense)
U.S. federal government COVID-19 grant	4,000
Amortization of debt discount		(72,078)
Financing costs	(43,815)	(182,064)
Cost of stock option modifications	(22,680)
Cost of stock warrant modification	(507,265)
Interest expense	(67,861)	(25,298)
Gain on debt forgiveness	56,840
Total other income (expense)	(580,781)	(279,440)
NET LOSS	(2,502,375)	(2,046,024)
Net loss attributable to non-controlling interest	281,299	63,860
Loss from deconsolidation of non-controlling interest		(405,383)
NET LOSS ATTRIBUTABLE TO WELLNESS CENTER USA, INC.	$ (2,221,076)	$ (2,387,547)
BASIC AND DILUTED LOSS PER SHARE	$ (0.02)	$ (0.02)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED	110,486,481	105,421,218
Trade [Member]
Sales:
Total Sales	$ 5,000	$ 19,508
Consulting Services [Member]
Sales:
Total Sales		$ 13,867

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total WCUI Deficit [Member]	Non-controlling Interest [Member]	Total
Balance at Sep. 30, 2018	$ 100,952	$ 22,450,252	$ (22,974,740)	$ (423,536)	$ (401,624)	$ (825,160)
Balance, shares at Sep. 30, 2018	100,952,569
Common shares issued for cash	$ 143	9,857		10,000		10,000
Common shares issued for cash, shares	142,857
Shares issued upon conversions of note payable	$ 4,811	285,361		290,172		290,172
Shares issued upon conversions of note payable, shares	4,810,222
Fair value of common stock issued with convertible note payable	$ 314	21,686		22,000		22,000
Fair value of common stock issued with convertible note payable, shares	314,286
Fair value of additional shares issued upon conversions of note payable		160,064		160,064		160,064
Fair value of vested stock options		300,925		300,925		300,925
Fair value of common stock issued for services	$ 1,277	77,752		79,029		79,029
Fair value of common stock issued for services, shares	1,277,143
Termination of non-controlling interest agreement			(405,383)	(405,383)	405,383
Contribution of capital by joint venture partners		471,750		471,750	453,250	925,000
Net loss			(1,982,164)	(1,982,164)	(63,860)	(2,046,024)
Balance at Sep. 30, 2019	$ 107,497	23,777,647	(25,362,287)	(1,477,143)	393,149	(1,083,994)
Balance, shares at Sep. 30, 2019	107,497,077
Fair value of vested stock options		263,414		263,414		263,414
Contribution of capital by joint venture partners		99,900		99,900	70,100	170,000
Fair value of common stock issued for services to Officers and Directors	$ 9,895	286,955		296,850		296,850
Fair value of common stock issued for services to Officers and Directors, shares	9,895,000
Fair value of common stock issued for services to consultants	$ 285	22,515		22,800		22,800
Fair value of common stock issued for services to consultants, shares	285,000
Fair value of warrants issued upon conversion of loan payable from shareholder		43,815		43,815		43,815
Cost of stock option modifications		22,680		22,680		22,680
Cost of stock warrant modification		507,265		507,265		507,265
Conversion of loan payable from shareholder into common shares	$ 575	29,425		30,000		30,000
Conversion of loan payable from shareholder into common shares, shares	575,000
Net loss			(2,221,076)	(2,221,076)	(281,299)	(2,502,375)
Balance at Sep. 30, 2020	$ 118,252	$ 25,053,616	$ (27,583,363)	$ (2,411,495)	$ 181,950	$ (2,229,545)
Balance, shares at Sep. 30, 2020	118,252,077

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash Flows from Operating Activities
Net loss	$ (2,502,375)	$ (2,046,024)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	1,562	1,057
Gain on debt forgiveness	(56,840)
Amortization of right-of-use asset	20,880
Amortization of debt discount		72,078
Fair value of common shares issued for services	319,650	79,029
Fair value of stock options issued for services	263,414	300,925
Fair value of additional shares issued upon conversions of note payable		160,064
Fair value of warrants issued upon conversion of loan payable from shareholder	43,815	22,000
Loss on abandonment of lease	438,296	65,000
Cost of stock option modifications	22,680
Cost of warrant modification	507,265
(Increase) Decrease in:
Inventories	(39,560)
Prepaid expenses and other assets	(500)	(36,690)
(Decrease) Increase in:
Accounts payable and accrued expenses	8,100	171,872
Payroll taxes payable	(10,500)
Lease liability	(20,880)
Deferred revenue		(8,624)
Net cash used in operating activities	(1,004,993)	(1,219,313)
Cash Flows from Financing Activities
Proceeds from loans payable from officers and shareholders	796,000	358,250
Repayment of loans payable from officers and shareholders		(25,000)
Proceeds from U.S. Small Business Administration PPP loan payable	37,166
Common stock and warrants issued for cash		10,000
Contribution of capital by joint venture partner	170,000	925,000
Net cash provided by financing activities	1,003,166	1,268,250
Net increase (decrease) in cash	(1,827)	48,937
Cash beginning of year	53,147	4,210
Cash end of year	51,320	53,147
Supplemental cash flows disclosures:
Interest paid
Taxes paid
Supplemental non-cash financing disclosures:
Initial recognition of right-of-use assets and operating lease liabilities upon adoption of ASC Topic 842	27,841
Reclassification of prepaid expenses to inventories	55,000
Conversion of loan payable from shareholder into common shares	30,000
Conversion of convertible note payable into common shares		$ 290,172

Basis of Presentation

Basis of Presentation	12 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	NOTE 1 – BASIS OF PRESENTATION Organization and Operations Wellness Center USA, Inc. (“WCUI” or the “Company”) was incorporated in June 2010 under the laws of the State of Nevada. The Company initially engaged in online sports and nutrition supplements marketing and distribution. The Company subsequently expanded into additional businesses within the healthcare and medical sectors through acquisitions, including Psoria-Shield Inc. (“PSI”) and StealthCo Inc. (“SCI”), d/b/a Stealth Mark, Inc. The Company currently operates in the following business segments: (i) distribution of targeted Ultra Violet (“UV”) phototherapy devices for dermatology and sanitation purposes; and (ii) authentication and encryption products and services. The segments are operated, respectively, through PSI and SCI. Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, the Company has not yet generated significant revenues and has incurred recurring net losses. During the year ended September 30, 2020, the Company incurred a net loss of $2,502,375 and used cash in operations of $1,004,993, and had a shareholders’ deficit of $2,229,545 as of September 30, 2020. In addition, $369,250 of notes payable to officers and shareholders and $92,334 of payroll taxes are past due. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s September 30, 2020 financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern. At September 30, 2020, the Company had cash on hand in the amount of $51,320. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and raising additional capital soon to meet its obligations and repay its liabilities arising from normal business operations when they come due. Since inception, we have funded our operations primarily through equity and debt financings and we expect to continue to rely on these sources of capital in the future. During the year ended September 30, 2020, the Company received $1,003,166 through short-term loans and contributions of capital by a joint venture partner. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stock holders, in case of equity financing.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Consolidation The consolidated financial statements include the Company’s wholly owned subsidiaries and the accounts of its subsidiaries for which it was determined that Company has operational and management control. The Company’s consolidated subsidiaries and/or entities are as follows: Name of consolidated subsidiary or entity State or other jurisdiction of incorporation or organization Date of incorporation or formation (date of acquisition/disposition, if applicable) Attributable interest at September 30, Attributable interest at September 30, Psoria-Shield Inc. (“PSI”) The State of Florida June 2009 (August 2012) 100 % 51 % (1) StealthCo, Inc. (“StealthCo”) The State of Illinois March 2014 100 % 100 % Psoria Development Company LLC. (“PDC”) The State of Illinois January 2015/November 2018 0 % 0 % NEO Phototherapy LLC (“NEO”) The State of Illinois December 2018 51 % (1) 0 % Protec Scientific, Inc (“Protec”) The State of New York April 2020 0 % 38 % (1) - Effective April 30, 2020, the Company's 51% interest in NEO was converted into a 51% interest in PSI. Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence reserves, accruals for potential liabilities, valuations of stock-based compensation, and realization of deferred tax assets, among others. Actual results could differ from these estimates. Income (Loss) Per Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the years ended September 30, 2020 and 2019, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At September 30, 2020 and 2019, the dilutive impact of outstanding stock options of 14,127,738 and 15,237,738 shares, respectively, and outstanding warrants for 67,634,049 and 66,484,049 shares, respectively, have been excluded because their impact on the loss per share is anti-dilutive. Revenue Recognition In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). For trade sales, the Company generates its revenue from sales contracts with customers with revenues being generated upon the shipment of merchandise, or for c We sell our products through two main sales channels: 1) directly to customers who use our products (the “Direct Channel”) and 2) to distribution partners who resell our products (the “Indirect Channel”). Under the Direct Channel, we sell our products to and we receive payment directly from customers who purchase our products. Under our Indirect Channel, we have entered into distribution agreements that allow the distributors to sell our products and fulfill performance obligations under the agreements. We determine revenue recognition through the following steps: ● Identification of the contract, or contracts, with a customer ● Identification of the performance obligations in the contract ● Determination of the transaction price ● Allocation of the transaction price to the performance obligations in the contract ● Recognition of revenue when, or as, we satisfy a performance obligation. Revenue is generally recognized upon shipment or when a service has been completed, unless we have significant performance obligations for services still to be completed. We recognize revenue when a material reversal is no longer probable. Payments received before the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue. There was no deferred revenue at September 30, 2020 and 2019. Inventories Inventories are stated at the lower of cost or net realizable value. Cost is computed on a first-in, first-out basis. At September 30, 2020, primarily all of the inventories totaling to $94,560 consisted of raw materials or work-in-progress. The Company provides inventory reserves based on excess and obsolete inventories determined primarily by future demand forecasts. The write down amount, if any, is measured as the difference between the cost of the inventory and market based upon assumptions about future demand and charged to the provision for inventory, which is a component of cost of sales. At the point of the loss recognition, a new, lower cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. At September 30, 2020, no reserve was recorded for slow moving and obsolete inventory. Property and Equipment Property and equipment are carried at cost less accumulated depreciation and amortization. The total cost of property and equipment at September 30, 2020 and 2019 was $106,720, and total accumulated depreciation at September 30, 2020 and 2019 was $106,720 and $105,158, respectively. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The Company has determined the estimated useful lives of its property and equipment, as follows: Computer equipment 5 years Medical equipment 5 years Furniture and fixtures 7 years Vehicles 3 years Software 3 years Depreciation expense for the years ended September 30, 2020 and 2019 was $1,562 and $1,057, respectively. Maintenance and repairs are charged to expense as incurred. The cost and accumulated depreciation of assets sold or otherwise disposed of are removed from the related accounts and the resulting gain or loss is reflected in the statements of operations. Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value. Income Taxes Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a valuation allowance against its deferred tax assets as of September 30, 2020 and 2019. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50 percent likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes. Fair Value measurements The Company determines the fair value of its assets and liabilities based on the exchange price in U.S. dollars that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value: ● Level 1 — ● Level 2 — ● Level 3 — The carrying amounts of financial instruments such as cash, and accounts payable and accrued liabilities, approximate the related fair values due to the short-term maturities of these instruments. The carrying value of the loans payable from officers and shareholders approximate their fair value based on the fair market interest rates of these obligations. Non-controlling Interests PDC Through November 2018, non-controlling interest represented the non-controlling interest holder’s proportionate share of the equity of the Company’s majority-owned subsidiary, PDC. Non-controlling interest is adjusted for the non-controlling interest holder’s proportionate share of the earnings or losses and other comprehensive income (loss), if any, and the non-controlling interest continues to be attributed its share of losses even if that attribution results in a deficit non-controlling interest balance. On November 15, 2018, PSI and TMA entered into a Withdraw and Mutual Release Agreement to terminate their joint venture agreement. On the date of termination, the non-controlling interest’s share of the accumulated losses of the joint venture totaled to $405,383. Upon termination, during the year ended September 30, 2019, the Company wrote-off the non-controlling interest’s share of the accumulated losses and recorded a loss from the deconsolidation of a non-controlling interest of $405,383. PSI In December 2018, PSI entered into a Joint Venture Agreement with GEN2 to further development, marketing, licensing and/or sale of PSI technology and products. Pursuant to the Joint Venture Agreement, the venture will be conducted through NEO Phototherapy, Inc. (“NEO”). PSI and GEN2 will be the members of NEO, owning 50.5% and 36.0%, respectively, of the Units issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants. Until such shares are distributed, the Company controls 68% of the joint venture and GEN2 the remaining 32%. PSI and GEN2 will manage NEO’s day-to-day operations. PSI will contribute PSI technology to NEO and GEN2 will contribute $700,000. As of December 31, 2019, NEO’s operations required additional funding above the $700,000 documented in the agreement, and as of September 30, 2019, GEN2 had received $925,000 of investments to contribute to NEO. During the year ended September 30, 2020, an additional $50,000 was contributed by GEN2 to NEO. As of September 30, 2020, GEN2 had received $975,000 of investments to contribute to NEO. As of April 30, 2020, the Company controlled 51% of the joint venture, GEN2 controlled 39% and another individual controlled the remaining 10%. The Company recorded its proportionate share of the contributions received of $497,250 to additional paid-in-capital and $477,750 to non-controlling interest as of September 30, 2019. Effective April 30, 2020, the joint venture with GEN2 was reorganized. GEN2 shareholders exchanged their common shares in GEN2, and the individual exchanged his membership interests in NEO, for common shares representing 49% ownership in PSI. The Company retained its common shares in PSI, which provides the Company a 51% economic interest in the PSI technology and products developed by the joint venture. During year ended September 30, 2020, the entities recorded a combined loss of $333,809 relating to its operations, of which $163,556 was allocated to the non-controlling interest. Repayment of the $975,000 investment will begin through and upon the date which PSI has realized and retained cumulative net income/distributable cash in the amount of $300,000. The minority interest of PSI ownership consists of accredited investors, and investment participation of $750,000 from several WCUI officers and directors, including Calvin R. O’Harrow and Roy M. Harsch. In May 2020, the Company’s subsidiary, PSI, agreed to become a majority shareholder in Protec Scientific, Inc. (“Protec”), a company formed in April 2020 by John Yorke for the purpose of designing, developing and marketing products that use spectral photonic emissions across a variety of applications. As of September 30, 2020, PSI had advanced $191,000 to Protec in furtherance of its agreement to acquire approximately 62% of Protec, with the Company’s share being approximately 32%, based on its PSI ownership. The remaining 30% share is to be attributed to PSI’s minority shareholders, based on their PSI ownership. During the year ended September 30, 2020, Protec received an additional $120,000 from non-affiliated investors, of which $74,400 was recorded to additional paid-in capital and $45,600 to the non-controlling interests. The additional investments gave the non-controlling interests a 38% ownership interest in Protec. During the year ended September 30, 2020, Protec recorded a loss of $172,174, of which $117,732 was allocated to the non-controlling interests. Stock-Based Compensation The Company periodically issues stock-based compensation to officers, directors, and consultants for services rendered, and as part of financing transactions. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors, employees, and for acquiring goods and services from non-employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values in accordance with Topic 718. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of the Company’s common stock option and warrant grants are estimated using a Black-Scholes Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, estimated forfeitures and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes Merton option pricing model could materially affect compensation expense recorded in future periods. Leases In February 2016, the FASB issued ASU No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than twelve months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for leases existing at, or entered into after, the beginning of the earliest period presented in the financial statements. The Company adopted ASU 2016-02 effective October 1, 2019. As a result, we recorded a right-of-use asset of $27,841, and a lease liability of the same amount, as of that date. In accordance with ASU 2016-02, the right-of-use asset is being amortized over the life of the underlying lease, and monthly lease payments are being recorded as reductions to the lease liability and imputed interest expense. See Note 6 for additional information. Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard is effective for interim and annual reporting periods beginning after December 15, 2019. The adoption of ASU 2016-13 is not expected to have a material impact on the Company’s financial position, results of operations, and cash flows. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Loans Payable from Officers and

Loans Payable from Officers and Shareholders	12 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Loans Payable from Officers and Shareholders	NOTE 3 – LOANS PAYABLE FROM OFFICERS AND SHAREHOLDERS As of September 30, 2018, loans payable from officers and shareholders of $66,000 were outstanding. During the year ended September 30, 2019, the Company borrowed $358,250 from its officers and shareholders and repaid $25,000. All of the loans are unsecured, have an interest rate of eight percent per annum and are due one year from the date of issuance. As of September 30, 2019, loans payable to officers and shareholders of $399,250 were outstanding. During the year ended September 30, 2020, the Company and its subsidiary, PSI, borrowed $796,000 from its officers and shareholders. The loans have an interest rate of eight percent per annum and are due one year from the date of issuance. During the year ended September 30, 2020, one of the loan holders who is not an officer or director, converted his loan in the amount of $30,000 into 575,000 shares of the Company’s common stock. In connection with the conversion of the loan payable, the Company issued the loan holder a warrant to purchase 1,150,000 shares of common stock as an inducement to convert. The warrants have an exercise price of $0.07 per share and expire five years from the date of grant. The fair value of the warrants of $43,815 was recorded as a financing cost during the year ended September 30, 2020 and was based on a probability affected Black-Scholes Merton pricing model with a stock price of $0.04, volatility of 187.0% and a risk-free rate of 0.20%. As of September 30, 2020, loans payable to officers and shareholders of $1,165,250 were outstanding. All of the loans are unsecured, have an interest rate of eight percent per annum and are due one year from the date of issuance. As of September 30, 2020, the Company’s officers and directors had the following loans outstanding: Calvin O;Harrow - $590,250; Roy Harsch - $205,000; William Kingsford - $201,000; Paul Jones - $100,000; Douglas Samuelson - $40,000; Tom Scott - $20,000. As of September 30, 2020, $369,250 of these loans were past due.

U.S. Small Business Administrat

U.S. Small Business Administration Loan Payable	12 Months Ended
	Sep. 30, 2020
U.s. Small Business Administration Loan Payable
U.S. Small Business Administration Loan Payable	NOTE 4 – U.S. SMALL BUSINESS ADMINISTRATION LOAN PAYABLE During the year ended September 30, 2020, the Company’s subsidiary, PSI, entered into a loan agreement with the United States Small Business Administration (SBA) under which the Company borrowed $37,166. The loan is unsecured, accrues interest at 1.0% and is due on April 23, 2022. Beginning in October 2020, PSI is required to make monthly interest payments and all principal and unpaid interest is due in April 2022. If PSI meets certain criteria as defined in the agreement, the loan may be forgiven at which time the Company would recognize a gain on debt forgiveness. As of the date of this filing, the Company had not yet applied for forgiveness of the loan.

Convertible Note Agreements

Convertible Note Agreements	12 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Convertible Note Agreements	NOTE 5 – CONVERTIBLE NOTE AGREEMENTS In March 2018, the Company entered into a Convertible Note Payable Agreement with an individual under which the Company borrowed $165,000. The agreement had an initial maturity date of October 2018. Relating to the agreement, the Company recognized a debt discount of $165,000 at the date of issuance. The balance of the unamortized discount at September 30, 2018 was $3,837. During the year ended September 30, 2019, the Company amended the terms of the agreement by extending the maturity date to January 2019 and reducing the conversion price from $0.10 per share to $0.07 per share. The reduction of the conversion price caused the Company to issue an additional 744,732 shares, which on the dates of amendment had a combined total fair value of $51,434, which was recorded a financing cost during the year ended September 30, 2019. During the year ended September 30, 2019, the individual converted $165,000 of the convertible note payable and $8,783 of accrued interest into 2,482,441 shares of the Company’s common stock (including the 744,732 shares discussed above). During the year ended September 30, 2019, the Company amortized the remaining $3,837 of debt discount, leaving no unamortized balance at September 30, 2019. No amounts were outstanding under the agreement as of September 30, 2019. In July 2018, the Company entered into another Convertible Note Payable Agreement with the same individual under which the Company borrowed an additional $110,000. The agreement had an initial maturity date of February 2019. Relating to the agreement, the Company recognized a debt discount of $110,000 at the date of issuance. The balance of the unamortized discount at September 30, 2018 was $68,241. .During the year ended September 30, 2019, the Company amended the terms of the agreement by reducing the conversion price from $0.15 per share to $0.05 per share. The reduction of the conversion price caused the Company to issue an additional 1,551,854 shares, which on the date of amendment had a fair value of $108,630, which was recorded a financing cost during the year ended September 30, 2019. During the year ended September 30, 2019, the Company amortized $68,241 of debt discount, leaving no unamortized balance at September 30, 2019. During the year ended September 30, 2019, the individual converted the note payable of $110,000 and $6,389 of accrued interest into 2,327,781 shares of the Company’s common stock (including the 1,551,854 shares discussed above). No amounts were outstanding under the agreement as of September 30, 2019.

Lease Liabilities

Lease Liabilities	12 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Lease Liabilities	NOTE 6 – LEASE LIABILITIES Operating Lease In February 2019, the Company’s PSI subsidiary entered into a , which requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease initially measured at the present value of the lease payments. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. Rent expense for the year ended September 30, 2020 was $21,600. During the year ended September 30, 2020, the Company reflected amortization of the right of use asset of $20,880, related to this lease, resulting in a net asset balance of $6,961 as of September 30, 2020. Other Leases The Company leased its corporate office facility in Hoffman Estates, Illinois pursuant to a non-cancellable lease initiated in July 2016 and expiring February 28, 2024. The lease terms require a monthly payment of approximately $11,000. The Company vacated the facility in April 2019, in favor of its present facilities in Tucson AZ, which are provided by a shareholder on a rent-free basis. The Company is in negotiations with the owners regarding the settlement of its lease obligations and expects that the property will be subleased or a settlement with the landlord will be reached at an amount significantly less than the remaining payment obligations. At the date of abandonment, the Company had a remaining lease obligation of $631,587. During the year ended September 30, 2019, the Company recorded an accrual for its estimate for the potential settlement of this matter and wrote-off its $15,000 security deposit relating to the lease. On or about June 29, 2020, we received notice that Hanover Hoffman Estates, LLC (“HHE”), filed case number 2020L006092 in the Circuit Court of Cook County alleging our failure to pay Base Rent and abandonment of certain office space in Hoffman Estates, Illinois subject to a Commercial Lease dated May 26, 2016. HHE seeks at least $672,878 in base rent and other amounts under the lease, as well as treble damages from our ex-CEO and two past Directors who were serving on our Board as of the date of the lease. We are currently evaluating the allegations, defenses and alternate actions. During the year ended September 30, 2020, the Company recorded an additional expense of $438,296 relating to the lease obligation, and recorded the full amount of the judgement due as of September 30, 2020. Commencing on October 1, 2016, the Company’s wholly-owned subsidiary, StealthCo, entered into a non-cancellable lease agreement to lease its office facilities in Oak Ridge, Tennessee. The term of the lease is five years and expires September 30, 2021. On January 6, 2020, the Company entered into an agreement with the owners to terminate the agreement effective January 1, 2020. Under the agreement, the Company agreed to pay $11,000 and abandon certain Company property as documented in the agreement. During the year ended September 30, 2020, the $11,000 was paid by the Company.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Shareholders' Equity	NOTE 7 – SHAREHOLDERS’ EQUITY Authorized shares On September 3, 2019, the Company’s Board of Directors unanimously approved the amendment of its Articles of Incorporation to increase the total authorized capital stock from 185,000,000 common shares to 200,000,000 common shares. As of September 18, 2019, holders of a majority of the outstanding shares of voting capital stock executed written stockholder consents approving this action and the Company amended its Articles of Incorporation through a filing of a Certificate of Amendment on October 11, 2019. Holders of shares of common stock have full voting rights, one vote for each share held of record. Shareholders are entitled to receive dividends as may be declared by the Board out of funds legally available therefore and share pro rata in any distributions to shareholders upon liquidation. Shareholders have no conversion, pre-emptive or subscription rights. All outstanding shares of common stock are fully paid and non-assessable. As of September 30, 2020 and 2019, there were 118,252,077 and 107,497,077 shares of common stock issued and outstanding, respectively. Common Shares Issued for Cash During the year ended September 30, 2019, the Company received $10,000 from the sale of 142,857 shares of its common stock. In connection with the sale, the Company issued a warrant to the shareholder to purchase 284,714 shares of the Company’s common stock. The warrant expires five years from the date of grant and has an exercise price of $0.15 per share. Common Shares Issued for Services During the year ended September 30, 2019, the Company issued 1,277,143 shares of its common stock valued at $79,029 for services provided by WCUI consultants. The shares were valued at the trading price of the common stock at the date of issuance and were recorded as compensation expense during the year ended September 30, 2019. During the year ended September 30, 2020, the Company issued 285,000 shares of its common stock valued at $22,800 for services provided by PSI consultants. The shares were valued at the trading price of the common stock at the date of issuance and were recorded as compensation expense during the year ended September 30, 2020. Restricted Stock Grants to Officers and Directors In April 2020, the Company’s Board of Directors approved the issuance of a combined total of 20,170,000 restricted shares of the Company’s common stock to its Officers and Directors. A total of 7,120,000 shares vested in April 2020, and a total of 1,800,000 will vest monthly from April 2020 through March 2021, and a total of 11,250,000 will vest monthly from April 2020 through March 2023. Of the 13,050,000 shares that vest over time, a total of 2,775,000 shares vested during the year ended September 30, 2020. The following table summarizes restricted common stock activity: Number of Restricted Shares Fair Value Weighted Average Grant Date Fair Value Non-vested, September 30, 2019 - $ - $ - Granted 20,170,000 605,100 0.03 Vested (9,895,000 ) (296,850 ) 0.03 Forfeited - - - Non-vested, September 30, 2020 10,275,000 $ 308,250 $ 0.03 Stock Options On December 22, 2010, the Company’s Board of Directors approved the adoption of the “2010 Non-Qualified Stock Option Plan” (“2010 Option Plan”) by unanimous consent. The 2010 Option Plan was initiated to encourage and enable officers, directors, consultants, advisors and key employees of the Company to acquire and retain a proprietary interest in the Company by ownership of its common stock. A total of 7,500,000 of the authorized shares of the Company’s common stock may be subject to, or issued pursuant to, the terms of the plan. Effective January 1, 2018, the Board of Directors approved to increase the number of authorized shares of the Company’s common stock that may be subject to, or issued pursuant to, the terms of the plan from 7,500,000 to 30,000,000. The Company’s policy is to recognize compensation cost for awards with only service conditions and a graded vesting schedule on a straight-line basis over the requisite service period for the entire award. Additionally, the Company’s policy is to issue new shares of common stock to satisfy stock option exercises. The Company applied fair value accounting for all share-based payments awards. The fair value of each option granted is estimated on the date of grant using the Black-Scholes option-pricing model. The table below summarizes the Company’s stock option activities for the years ended September 30, 2020 and 2019: Number of Option Shares Exercise Price Range Per Share Weighted Average Exercise Price Balance, September 30,2018 17,946,667 $ 0.10 - 2.00 $ 0.28 Granted 250,000 0.03 - 0.06 0.05 Cancelled (646,429 ) 0.14 - 0.19 0.17 Exercised - - - Expired (2,312,500 ) 0.13 - 0.40 0.37 Balance, September 30, 2019 15,237,738 0.03 - 2.00 0.28 Granted 5,000,000 0.04 - 0.09 0.05 Cancelled (4,910,000 ) 0.14 - 0.30 0.14 Exercised - - - Expired (1,200,000 ) 0.11 - 0.25 0.15 Balance, September 30, 2020 14,127,738 $ 0.03 – 2.00 $ 0.23 Vested and exercisable, September 30, 2020 10,702,738 $ 0.03 – 2.00 $ 0.29 Unvested, September 30, 2020 3,425,500 $ 0.04 $ 0.04 The following table summarizes information concerning outstanding and exercisable options as of September 30, 2020: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.03 - 0.39 12,665,238 5.54 $ 0.09 9,240,238 4.14 $ 0.11 0.40 - 0.99 62,500 1.50 0.40 62,500 1.50 0.40 1.00 - 1.99 750,000 0.25 1.00 750,000 0.25 1.00 2.00 650,000 0.25 2.00 650,000 0.25 2.00 $ 0.06 - 2.00 14,127,738 3.05 $ 0.23 10,702,738 3.61 $ 0.29 The aggregate intrinsic value for option shares outstanding at September 30, 2020 was $184,375. Stock Option Grants during Fiscal Year Ended September 30, 2019 During the year ended September 30, 2019, the Company granted options to an employee to purchase an aggregate total of 250,000 shares of its common stock with an aggregate fair value of $10,366. The options have exercise prices ranging from $0.03 to $0.06 per share and expire five years from the date of grant. The shares vested equally each quarter beginning on December 31, 2018. The Company valued the options using a Black-Scholes option pricing model. During the year ended September 30, 2019, the Company recorded $10,366 of stock compensation for the value of the options, and as of September 30, 2019, no unvested compensation remained that will be amortized over the remaining vesting period. The assumptions used for all of the options granted during the year ended September 30, 2019 are as follows: Exercise price $ 0.03 - $0.06 Expected dividends - Expected volatility 126.8% – 144.0 % Risk free interest rate 1.60 % - 2.47 % Expected life of options 2.5 Stock Option Activity during Fiscal Year Ended September 30, 2020 During the year ended September 30, 2020, the Company’s Board of Directors approved the cancellation of stock options to purchase 3,360,000 shares of the Company’s common stock with an exercise prices of $0.14 and $0.30 per share that had vested as of March 31, 2020, and 1,550,000 shares with an exercise price of $0.14 per share that were set to vest monthly from April 2020 through March 2021. All of the cancelled options were held by the Company’s Officers and Directors. The Board approved the grant of stock options to its Chief Executive Officer to purchase 4,250,000 shares with an exercise price of $0.04 per share that expire ten years from the date of grant. The fair value of the shares was determined to be $127,500 as of the date of grant based on a Black-Scholes option model. A total of 1,125,000 shares vested during the year ended September 30, 2020 and 3,125,000 shares will vest monthly over the period from October 2020 through March 2023. Subsequent to the grant of these shares, the Board approved the following modifications relating to the Chief Executive Officer’s options: a. Repricing of stock options to purchase 1,200,000 shares with an exercise price of $0.14 per share to $0.04 per share that had vested as of March 31, 2020, b. Repricing of stock options to purchase 600,000 shares with an exercise price of $0.14 per share to $0.04 per share that were set to vest monthly from April 2020 through March 2021. c. Extend the expiration of the options to ten years from the date of grant, rather than the five-year expiration the shares initially had. In accounting for the modification, the Company calculated for the fair value of the options before modification using current valuation inputs including the Company’s closing stock price of $0.03 on May 28, 2020, a volatility metric of 183%, and a risk-free interest rate of 0.34%. The Company also calculated the fair value of the options after modification using the extended term and modified exercise price. The incremental fair value of the options resulting from the modifications was $22,680 that was recognized as an expense during the year ended September 30, 2020. In addition to the options granted to the Company’s Chief Executive Officer noted above, during the year ended September 30, 2020, the Company granted options to several employee to purchase a total of 750,000 shares of its common stock with an aggregate fair value of $59,376. The options have an exercise price of $0.04 and $0.09 per share and expire five years from the date of grant. The shares vested on the date of grant. The Company valued the options using a Black-Scholes option pricing model. The assumptions used for all of the options granted during the year ended September 30, 2020 are as follows: Exercise price $ 0.04 - $0.09 Expected dividends - Expected volatility 157.6% – 197.0 % Risk free interest rate 0.17 % - 1.60 % Expected life of options 2.5 During the years ended September 30, 2020 and 2019, the Company recorded in the aggregate $263,414 and $300,925, respectively of stock compensation for options vesting during those years, and as of September 30, 2020, unvested compensation of $96,764 remained that will be amortized over the remaining vesting period. Stock Warrants The table below summarizes the Company’s warrants activities for the year ended September 30, 2020: Number of Warrant Shares Exercise Price Range Per Share Weighted Average Exercise Price Balance, September 30, 2018 67,907,728 $ 0.12 - 1.00 $ 0.17 Granted 284,714 0.15 0.15 Cancelled - - - Exercised - - - Expired (1,708,393 ) 0.30 - 0.67 0.44 Balance, September 30, 2019 66,484,049 $ 0.12 - 0.40 $ 0.17 Granted 1,150,000 0.07 0.07 Cancelled - - - Exercised - - - Expired - - - Balance, September 30, 2020 67,634,049 $ 0.07 - 0.40 $ 0.16 Vested and exercisable, September 30, 2020 67,634,049 $ 0.07 - 0.40 $ 0.16 During the year ended September 30, 2019, the Company issued a warrant to purchase 284,714 shares with an exercise price of $0.15 per share as part of the sale of equity units. The warrant expires five years from the date of grant. During the year ended September 30, 2020, in connection with the conversion of a loan payable, the Company issued a warrant to purchase 1,150,000 shares with an exercise price of $0.07 per share with a fair value of $43,815. The warrant expires five years from the date of grant. Effective January 1, 2020, the Company’s Board of Directors approved the extension of the Company’s unexpired stock warrants as of December 31, 2019, by an additional one year period. This change affected approximately 66,000,000 warrant shares including approximately 20,000,000 warrant shares that were set to expire by the year ending September 30, 2020. The 66,000,000 warrant shares had exercise prices ranging from $0.12 per share to $0.40 per share. The incremental fair value of the warrants resulting from modification was $507,265 and was recognized as an expense during the year ended September 30, 2020. There was no aggregate intrinsic value for warrant shares outstanding at September 30, 2020. The following table summarizes information concerning outstanding and exercisable warrants as of September 30, 2020: Warrants Outstanding Warrants Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.12 – 0.20 60,429,384 1.97 $ 0.15 60,429,384 1.97 $ 0.15 0.21 – 0.40 7,204,665 0.88 0.26 7,204,665 0.88 0.26 $ 0.12 – 0.40 67,634,049 1.85 $ 0.16 67,634,049 1.85 $ 0.16

Segment Reporting

Segment Reporting	12 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Segment Reporting	NOTE 8 – SEGMENT REPORTING Reportable segments are components of an enterprise about which separate financial information is available and that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company. The Company operates in the following business segments: (i) Medical Devices: (ii) Authentication and Encryption Products and Services: The detailed segment information of the Company is as follows: Assets By Segment September 30, 2020 Corporate Medical Devices Authentication and Encryption Total ASSETS Current Assets Cash $ 1,079 $ 44,444 $ 5,797 $ 51,320 Inventories - 94,560 - 94,560 Prepaid expenses and other current assets 500 - - 500 Total current assets 1,579 139,004 5,797 146,380 Right-of-use asset - 6,961 - 6,961 Total other assets - 6,961 - 6,961 TOTAL ASSETS $ 1,579 $ 145,965 $ 5,797 $ 153,341 Operations by Segment For the Year Ended September 30, 2020 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ - $ 5,000 $ 5,000 Consulting services - - - - Total Sales - - 5,000 5,000 Cost of goods sold - - - - Gross profit - - 5,000 5,000 Operating expenses 1,004,477 852,542 69,575 1,926,594 Loss from operations $ (1,004,477 ) $ (852,542 ) $ (64,575 ) $ (1,921,594 ) Operations by Segment For the Year Ended September 30, 2019 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ - $ 19,508 $ 19,508 Consulting services - - 13,867 13,867 Total Sales - - 33,375 33,375 Cost of goods sold - - 20,025 20,025 Gross profit - - 13,350 13,350 Operating expenses 782,961 641,236 355,737 1,779,934 Loss from operations $ (782,961 ) $ (641,236 ) $ (342,387 ) $ (1,766,584 )

Legal Matters

Legal Matters	12 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Legal Matters	NOTE 9 – LEGAL MATTERS The Company is periodically engaged in legal proceedings arising from and relating to its business operations. Except as otherwise described herein, we currently are not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or any of our subsidiaries, threatened against or affecting our Company, our common stock, any of our subsidiaries or of our Company’s or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect on our financial condition or results of operations. We continue efforts to preserve revenue and reduce operating expenses through actions including, but not limited to, facilities consolidation and staff reductions, which we hope to implement through negotiated transactions with lessors, employees and other third parties. Such actions may result in disputes with and claims by such parties which, if not resolved through negotiations, may impact negatively the Company’s ability to continue as a going concern. To date, the Company has negotiated settlement of all ex-employee wage and benefits claims except for two. The first regards unpaid wages claimed due together with interest at the rate of 4% per annum on such amount as the Company originally agreed upon in settlement negotiations. The ex-employee claims additional amounts due for certain statutory damages under the Illinois Wage Payment and Collection which currently could exceed $21,600.00 and would increase at the rate of 2% of the wages due per month plus attorneys’ fees if the employee elects to file suit for a violation of the Act and is successful in obtaining a judgment on his claim. The second claim was filed with the Illinois Department of Labor asserting a violation of the Illinois Wage Payment and Collection Act by the Company’s former CEO. That claim alleges unpaid wages in the amount of $158,714.60 and unpaid vacation pay in the amount of $20,833.33 for a total amount of $179,547.90, as well as certain statutory damages including, put not limited to, 2% of the wages due per month plus attorneys’ fees if the ex-CEO elects to file suit for a violation of the Act and is successful in obtaining a judgment on his claim. The Company has filed its response to such claim with the Department denying the substantive allegations therein and asserting certain factual and legal defenses, including breach of fiduciary duty, as a bar to all claimed compensation. The claim remains pending, but as the date hereof, no suit has been filed against the Company asserting a violation of the Act based on said claim. In periodic reports on Forms 10K and 10Q for the periods ending September 30, 2017 and December 31, 2017, respectively, the Company disclosed that on May 25, 2017, the SEC’s Chicago Regional Office informed it that it had made a preliminary determination to recommend filing of an enforcement action against the Company and its former CEO based on possible violations of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and Section 17(a) of the Securities Act, and Section 15(a) of the Exchange Act. Subsequent discussions resulted in the submission of an Offer of Settlement (“Settlement”) through an administrative cease and desist action on November 17, 2017, which was accepted by the SEC on April 12, 2018, as disclosed on Form 8K filed April 18, 2018. Pursuant to the Settlement, the Company neither admitted nor denied any of the allegations, but was enjoined from violating the above-referenced Sections and Rule. The Settlement imposed no financial penalties or sanctions against the Company. The former CEO was the subject of a separate SEC complaint in the U.S. District Court for the Northern District of Illinois, asserting the allegations noted above, as well as allegations that he manipulated the price of company shares through undisclosed trading, realizing more than $130,000 from such trading. On the date of filing, the CEO voluntarily resigned as an officer and director of the Company. Without admitting or denying the allegations, the CEO consented to the entry of the judgment, which was entered on September 26, 2018 by the U.S. District Court for the Northern District of Illinois. The judgment permanently enjoined him from violating the anti-fraud provisions of Section 17(a) of the Securities Act of 1933, Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and the broker registration provisions of Section 15(a) of the Exchange Act. It also barred him from serving as an officer or director of a public company and from participating in penny stock offerings, and ordered disgorgement and interest and penalties to be determined by the court. On or about June 29, 2020, the Company received notice that Hanover Hoffman Estates, LLC (“HHE”), filed case number 2020L006092 in the Circuit Court of Cook County alleging failure to pay Base Rent and abandonment of certain office space in Hoffman Estates, Illinois subject to a Commercial Lease dated May 26, 2016. HHE seeks at least $672,888 in base rent and other amounts under the lease, as well as treble damages from our ex-CEO and two past Directors who were serving on our Board as of the date of the lease. The Company has continued evaluation of the allegations, defenses and alternate actions, and it is engaged settlement negotiations which are on-going.

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 10 – INCOME TAXES At September 30, 2020, the Company had net operating loss (“NOL”) carryforwards for federal income tax purposes of approximately $20 million that may be offset against future taxable income through 2040. No tax benefit has been reported with respect to these net operating loss (NOL) carryforwards because the Company believes that the realization of the Company’s net deferred tax assets of approximately $5,000,000 was not considered more likely than not and accordingly, the potential tax benefits of the net loss carryforwards are offset by a full valuation allowance. The Company recognizes as income tax expense, interest and penalties on uncertain tax provisions. As of September 30, 2020, and 2019, the Company has not accrued interest or penalties related to uncertain tax positions. Tax years 2017 through 2020 remain open to examination by the major taxing jurisdictions to which the Company is subject. The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes as follows: September 30, September 30, Income tax benefit at federal statutory rate (21.0 )% (21.0 )% State income tax benefit, net of federal benefit (4.0 )% (4.0 )% Change in valuation allowance 25.0 % 25.0 % Income taxes at effective income tax rate - % - % The components of deferred taxes consist of the following at September 30, 2020 and 2019: September 30, September 30, Net operating loss carryforwards $ 5,117,750 $ 4,657,556 Less: Valuation allowance (5,117,750 ) (4,657,556 ) Net deferred tax assets $ - $ -

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 11 – SUBSEQUENT EVENTS Subsequent to September 30, 2020, the Company borrowed $375,000 from its officers and shareholders. All of the loans are unsecured, have an interest rate of eight percent per annum and are due one year from the date of issuance. As of the date of this filing, the Company’s officers and directors had the following loans outstanding: Calvin O;Harrow - $745,250; Roy Harsch - $235,000; William Kingsford - $291,000; Paul Jones - $100,000; Douglas Samuelson - $40,000; Thomas Scott - $20,000.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the Company’s wholly owned subsidiaries and the accounts of its subsidiaries for which it was determined that Company has operational and management control. The Company’s consolidated subsidiaries and/or entities are as follows: Name of consolidated subsidiary or entity State or other jurisdiction of incorporation or organization Date of incorporation or formation (date of acquisition/disposition, if applicable) Attributable interest at September 30, Attributable interest at September 30, Psoria-Shield Inc. (“PSI”) The State of Florida June 2009 (August 2012) 100 % 51 % (1) StealthCo, Inc. (“StealthCo”) The State of Illinois March 2014 100 % 100 % Psoria Development Company LLC. (“PDC”) The State of Illinois January 2015/November 2018 0 % 0 % NEO Phototherapy LLC (“NEO”) The State of Illinois December 2018 51 % (1) 0 % Protec Scientific, Inc (“Protec”) The State of New York April 2020 0 % 38 % (1) - Effective April 30, 2020, the Company's 51% interest in NEO was converted into a 51% interest in PSI.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence reserves, accruals for potential liabilities, valuations of stock-based compensation, and realization of deferred tax assets, among others. Actual results could differ from these estimates.
Income (Loss) Per Share	Income (Loss) Per Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the years ended September 30, 2020 and 2019, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At September 30, 2020 and 2019, the dilutive impact of outstanding stock options of 14,127,738 and 15,237,738 shares, respectively, and outstanding warrants for 67,634,049 and 66,484,049 shares, respectively, have been excluded because their impact on the loss per share is anti-dilutive.
Revenue Recognition	Revenue Recognition In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). For trade sales, the Company generates its revenue from sales contracts with customers with revenues being generated upon the shipment of merchandise, or for c We sell our products through two main sales channels: 1) directly to customers who use our products (the “Direct Channel”) and 2) to distribution partners who resell our products (the “Indirect Channel”). Under the Direct Channel, we sell our products to and we receive payment directly from customers who purchase our products. Under our Indirect Channel, we have entered into distribution agreements that allow the distributors to sell our products and fulfill performance obligations under the agreements. We determine revenue recognition through the following steps: ● Identification of the contract, or contracts, with a customer ● Identification of the performance obligations in the contract ● Determination of the transaction price ● Allocation of the transaction price to the performance obligations in the contract ● Recognition of revenue when, or as, we satisfy a performance obligation. Revenue is generally recognized upon shipment or when a service has been completed, unless we have significant performance obligations for services still to be completed. We recognize revenue when a material reversal is no longer probable. Payments received before the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue. There was no deferred revenue at September 30, 2020 and 2019.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. Cost is computed on a first-in, first-out basis. At September 30, 2020, primarily all of the inventories totaling to $94,560 consisted of raw materials or work-in-progress. The Company provides inventory reserves based on excess and obsolete inventories determined primarily by future demand forecasts. The write down amount, if any, is measured as the difference between the cost of the inventory and market based upon assumptions about future demand and charged to the provision for inventory, which is a component of cost of sales. At the point of the loss recognition, a new, lower cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. At September 30, 2020, no reserve was recorded for slow moving and obsolete inventory.
Property and Equipment	Property and Equipment Property and equipment are carried at cost less accumulated depreciation and amortization. The total cost of property and equipment at September 30, 2020 and 2019 was $106,720, and total accumulated depreciation at September 30, 2020 and 2019 was $106,720 and $105,158, respectively. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The Company has determined the estimated useful lives of its property and equipment, as follows: Computer equipment 5 years Medical equipment 5 years Furniture and fixtures 7 years Vehicles 3 years Software 3 years Depreciation expense for the years ended September 30, 2020 and 2019 was $1,562 and $1,057, respectively. Maintenance and repairs are charged to expense as incurred. The cost and accumulated depreciation of assets sold or otherwise disposed of are removed from the related accounts and the resulting gain or loss is reflected in the statements of operations. Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value.
Income Taxes	Income Taxes Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a valuation allowance against its deferred tax assets as of September 30, 2020 and 2019. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50 percent likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes.
Fair Value measurements	Fair Value measurements The Company determines the fair value of its assets and liabilities based on the exchange price in U.S. dollars that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value: ● Level 1 — ● Level 2 — ● Level 3 — The carrying amounts of financial instruments such as cash, and accounts payable and accrued liabilities, approximate the related fair values due to the short-term maturities of these instruments. The carrying value of the loans payable from officers and shareholders approximate their fair value based on the fair market interest rates of these obligations.
Non-controlling Interests	Non-controlling Interests PDC Through November 2018, non-controlling interest represented the non-controlling interest holder’s proportionate share of the equity of the Company’s majority-owned subsidiary, PDC. Non-controlling interest is adjusted for the non-controlling interest holder’s proportionate share of the earnings or losses and other comprehensive income (loss), if any, and the non-controlling interest continues to be attributed its share of losses even if that attribution results in a deficit non-controlling interest balance. On November 15, 2018, PSI and TMA entered into a Withdraw and Mutual Release Agreement to terminate their joint venture agreement. On the date of termination, the non-controlling interest’s share of the accumulated losses of the joint venture totaled to $405,383. Upon termination, during the year ended September 30, 2019, the Company wrote-off the non-controlling interest’s share of the accumulated losses and recorded a loss from the deconsolidation of a non-controlling interest of $405,383. PSI In December 2018, PSI entered into a Joint Venture Agreement with GEN2 to further development, marketing, licensing and/or sale of PSI technology and products. Pursuant to the Joint Venture Agreement, the venture will be conducted through NEO Phototherapy, Inc. (“NEO”). PSI and GEN2 will be the members of NEO, owning 50.5% and 36.0%, respectively, of the Units issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants. Until such shares are distributed, the Company controls 68% of the joint venture and GEN2 the remaining 32%. PSI and GEN2 will manage NEO’s day-to-day operations. PSI will contribute PSI technology to NEO and GEN2 will contribute $700,000. As of December 31, 2019, NEO’s operations required additional funding above the $700,000 documented in the agreement, and as of September 30, 2019, GEN2 had received $925,000 of investments to contribute to NEO. During the year ended September 30, 2020, an additional $50,000 was contributed by GEN2 to NEO. As of September 30, 2020, GEN2 had received $975,000 of investments to contribute to NEO. As of April 30, 2020, the Company controlled 51% of the joint venture, GEN2 controlled 39% and another individual controlled the remaining 10%. The Company recorded its proportionate share of the contributions received of $497,250 to additional paid-in-capital and $477,750 to non-controlling interest as of September 30, 2019. Effective April 30, 2020, the joint venture with GEN2 was reorganized. GEN2 shareholders exchanged their common shares in GEN2, and the individual exchanged his membership interests in NEO, for common shares representing 49% ownership in PSI. The Company retained its common shares in PSI, which provides the Company a 51% economic interest in the PSI technology and products developed by the joint venture. During year ended September 30, 2020, the entities recorded a combined loss of $333,809 relating to its operations, of which $163,556 was allocated to the non-controlling interest. Repayment of the $975,000 investment will begin through and upon the date which PSI has realized and retained cumulative net income/distributable cash in the amount of $300,000. The minority interest of PSI ownership consists of accredited investors, and investment participation of $750,000 from several WCUI officers and directors, including Calvin R. O’Harrow and Roy M. Harsch. In May 2020, the Company’s subsidiary, PSI, agreed to become a majority shareholder in Protec Scientific, Inc. (“Protec”), a company formed in April 2020 by John Yorke for the purpose of designing, developing and marketing products that use spectral photonic emissions across a variety of applications. As of September 30, 2020, PSI had advanced $191,000 to Protec in furtherance of its agreement to acquire approximately 62% of Protec, with the Company’s share being approximately 32%, based on its PSI ownership. The remaining 30% share is to be attributed to PSI’s minority shareholders, based on their PSI ownership. During the year ended September 30, 2020, Protec received an additional $120,000 from non-affiliated investors, of which $74,400 was recorded to additional paid-in capital and $45,600 to the non-controlling interests. The additional investments gave the non-controlling interests a 38% ownership interest in Protec. During the year ended September 30, 2020, Protec recorded a loss of $172,174, of which $117,732 was allocated to the non-controlling interests.
Stock-based Compensation	Stock-Based Compensation The Company periodically issues stock-based compensation to officers, directors, and consultants for services rendered, and as part of financing transactions. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors, employees, and for acquiring goods and services from non-employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values in accordance with Topic 718. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of the Company’s common stock option and warrant grants are estimated using a Black-Scholes Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, estimated forfeitures and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes Merton option pricing model could materially affect compensation expense recorded in future periods.
Leases	Leases In February 2016, the FASB issued ASU No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than twelve months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for leases existing at, or entered into after, the beginning of the earliest period presented in the financial statements. The Company adopted ASU 2016-02 effective October 1, 2019. As a result, we recorded a right-of-use asset of $27,841, and a lease liability of the same amount, as of that date. In accordance with ASU 2016-02, the right-of-use asset is being amortized over the life of the underlying lease, and monthly lease payments are being recorded as reductions to the lease liability and imputed interest expense. See Note 6 for additional information.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard is effective for interim and annual reporting periods beginning after December 15, 2019. The adoption of ASU 2016-13 is not expected to have a material impact on the Company’s financial position, results of operations, and cash flows. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Schedule of Company's Consolidated Subsidiaries	The Company’s consolidated subsidiaries and/or entities are as follows: Name of consolidated subsidiary or entity State or other jurisdiction of incorporation or organization Date of incorporation or formation (date of acquisition/disposition, if applicable) Attributable interest at September 30, Attributable interest at September 30, Psoria-Shield Inc. (“PSI”) The State of Florida June 2009 (August 2012) 100 % 51 % (1) StealthCo, Inc. (“StealthCo”) The State of Illinois March 2014 100 % 100 % Psoria Development Company LLC. (“PDC”) The State of Illinois January 2015/November 2018 0 % 0 % NEO Phototherapy LLC (“NEO”) The State of Illinois December 2018 51 % (1) 0 % Protec Scientific, Inc (“Protec”) The State of New York April 2020 0 % 38 % (1) - Effective April 30, 2020, the Company's 51% interest in NEO was converted into a 51% interest in PSI.
Schedule of Estimated Useful Lives of Property and Equipment	The Company has determined the estimated useful lives of its property and equipment, as follows: Computer equipment 5 years Medical equipment 5 years Furniture and fixtures 7 years Vehicles 3 years Software 3 years

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Summary of Restricted Common Stock	The following table summarizes restricted common stock activity: Number of Restricted Shares Fair Value Weighted Average Grant Date Fair Value Non-vested, September 30, 2019 - $ - $ - Granted 20,170,000 605,100 0.03 Vested (9,895,000 ) (296,850 ) 0.03 Forfeited - - - Non-vested, September 30, 2020 10,275,000 $ 308,250 $ 0.03
Schedule of Stock Option Activity	The table below summarizes the Company’s stock option activities for the years ended September 30, 2020 and 2019: Number of Option Shares Exercise Price Range Per Share Weighted Average Exercise Price Balance, September 30,2018 17,946,667 $ 0.10 - 2.00 $ 0.28 Granted 250,000 0.03 - 0.06 0.05 Cancelled (646,429 ) 0.14 - 0.19 0.17 Exercised - - - Expired (2,312,500 ) 0.13 - 0.40 0.37 Balance, September 30, 2019 15,237,738 0.03 - 2.00 0.28 Granted 5,000,000 0.04 - 0.09 0.05 Cancelled (4,910,000 ) 0.14 - 0.30 0.14 Exercised - - - Expired (1,200,000 ) 0.11 - 0.25 0.15 Balance, September 30, 2020 14,127,738 $ 0.03 – 2.00 $ 0.23 Vested and exercisable, September 30, 2020 10,702,738 $ 0.03 – 2.00 $ 0.29 Unvested, September 30, 2020 3,425,500 $ 0.04 $ 0.04
Schedule of Outstanding and Exercisable Options by Exercise Price Range	The following table summarizes information concerning outstanding and exercisable options as of September 30, 2020: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.03 - 0.39 12,665,238 5.54 $ 0.09 9,240,238 4.14 $ 0.11 0.40 - 0.99 62,500 1.50 0.40 62,500 1.50 0.40 1.00 - 1.99 750,000 0.25 1.00 750,000 0.25 1.00 2.00 650,000 0.25 2.00 650,000 0.25 2.00 $ 0.06 - 2.00 14,127,738 3.05 $ 0.23 10,702,738 3.61 $ 0.29
Schedule of Assumptions Used for Options Granted	The assumptions used for all of the options granted during the year ended September 30, 2019 are as follows: Exercise price $ 0.03 - $0.06 Expected dividends - Expected volatility 126.8% – 144.0 % Risk free interest rate 1.60 % - 2.47 % Expected life of options 2.5 The assumptions used for all of the options granted during the year ended September 30, 2020 are as follows: Exercise price $ 0.04 - $0.09 Expected dividends - Expected volatility 157.6% – 197.0 % Risk free interest rate 0.17 % - 1.60 % Expected life of options 2.5
Schedule of Warrant Activity	The table below summarizes the Company’s warrants activities for the year ended September 30, 2020: Number of Warrant Shares Exercise Price Range Per Share Weighted Average Exercise Price Balance, September 30, 2018 67,907,728 $ 0.12 - 1.00 $ 0.17 Granted 284,714 0.15 0.15 Cancelled - - - Exercised - - - Expired (1,708,393 ) 0.30 - 0.67 0.44 Balance, September 30, 2019 66,484,049 $ 0.12 - 0.40 $ 0.17 Granted 1,150,000 0.07 0.07 Cancelled - - - Exercised - - - Expired - - - Balance, September 30, 2020 67,634,049 $ 0.07 - 0.40 $ 0.16 Vested and exercisable, September 30, 2020 67,634,049 $ 0.07 - 0.40 $ 0.16
Schedule of Outstanding and Exercisable Warrants by Exercise Price Range	The following table summarizes information concerning outstanding and exercisable warrants as of September 30, 2020: Warrants Outstanding Warrants Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.12 – 0.20 60,429,384 1.97 $ 0.15 60,429,384 1.97 $ 0.15 0.21 – 0.40 7,204,665 0.88 0.26 7,204,665 0.88 0.26 $ 0.12 – 0.40 67,634,049 1.85 $ 0.16 67,634,049 1.85 $ 0.16

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Schedule of Assets of Reportable Segments	The detailed segment information of the Company is as follows: Assets By Segment September 30, 2020 Corporate Medical Devices Authentication and Encryption Total ASSETS Current Assets Cash $ 1,079 $ 44,444 $ 5,797 $ 51,320 Inventories - 94,560 - 94,560 Prepaid expenses and other current assets 500 - - 500 Total current assets 1,579 139,004 5,797 146,380 Right-of-use asset - 6,961 - 6,961 Total other assets - 6,961 - 6,961 TOTAL ASSETS $ 1,579 $ 145,965 $ 5,797 $ 153,341
Schedule of Operations of Reportable Segments	Operations by Segment For the Year Ended September 30, 2020 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ - $ 5,000 $ 5,000 Consulting services - - - - Total Sales - - 5,000 5,000 Cost of goods sold - - - - Gross profit - - 5,000 5,000 Operating expenses 1,004,477 852,542 69,575 1,926,594 Loss from operations $ (1,004,477 ) $ (852,542 ) $ (64,575 ) $ (1,921,594 ) Operations by Segment For the Year Ended September 30, 2019 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ - $ 19,508 $ 19,508 Consulting services - - 13,867 13,867 Total Sales - - 33,375 33,375 Cost of goods sold - - 20,025 20,025 Gross profit - - 13,350 13,350 Operating expenses 782,961 641,236 355,737 1,779,934 Loss from operations $ (782,961 ) $ (641,236 ) $ (342,387 ) $ (1,766,584 )

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Schedule of Effective Income tax Rate Reconcilliation	The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes as follows: September 30, September 30, Income tax benefit at federal statutory rate (21.0 )% (21.0 )% State income tax benefit, net of federal benefit (4.0 )% (4.0 )% Change in valuation allowance 25.0 % 25.0 % Income taxes at effective income tax rate - % - %
Schedule of Deferred Tax Assets and Liabilities	The components of deferred taxes consist of the following at September 30, 2020 and 2019: September 30, September 30, Net operating loss carryforwards $ 5,117,750 $ 4,657,556 Less: Valuation allowance (5,117,750 ) (4,657,556 ) Net deferred tax assets $ - $ -

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Entity incorporation, state country name	Nevada
Net loss	$ (2,502,375)	$ (2,046,024)
Cash used in operations	(1,004,993)	(1,219,313)
Shareholders' deficit	(2,229,545)	(1,083,994)	$ (825,160)
Notes payable to officers and shareholders	369,250
Payroll taxes due	92,334	102,834
Cash on hand	51,320	$ 53,147
Proceeds from short-term loans and contributions of capital by joint venture partner	$ 1,003,166

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Nov. 15, 2018	May 30, 2020	Dec. 31, 2019	Dec. 31, 2018	Sep. 30, 2020	Sep. 30, 2019	Apr. 30, 2020	Oct. 02, 2019
Deferred revenue
Inventories					94,560
Inventory reserves
Property and equipment gross					106,720	106,720
Accumulated depreciation					106,720	105,158
Depreciation expense					$ 1,562	1,057
Measurement of tax benefit, percentage of realized upon settlement, minimum, description					More than 50 percent
Non-controlling interest's share of accumulated losses of joint venture	$ 405,383
Loss from deconsolidation of non-controlling interest						405,383
Non-controlling interest, description				Pursuant to the Joint Venture Agreement, the venture will be conducted through NEO Phototherapy, Inc. ("NEO"). PSI and GEN2 will be the members of NEO, owning 50.5% and 36.0%, respectively, of the Units issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants. Until such shares are distributed, the Company controls 68% of the joint venture and GEN2 the remaining 32%. PSI and GEN2 will manage NEO's day-to-day operations. PSI will contribute PSI technology to NEO and GEN2 will contribute $700,000. As of December 31, 2019, NEO's operations required additional funding above the $700,000 documented in the agreement, and as of September 30, 2019, GEN2 had received $925,000 of investments to contribute to NEO. During the year ended September 30, 2020, an additional $50,000 was contributed by GEN2 to NEO. As of September 30, 2020, GEN2 had received $975,000 of investments to contribute to NEO. As of April 30, 2020, the Company controlled 51% of the joint venture, GEN2 controlled 39% and another individual controlled the remaining 10%. The Company recorded its proportionate share of the contributions received of $497,250 to additional paid-in-capital and $477,750 to non-controlling interest as of September 30, 2019.
Contributed capital				$ 700,000
Operating loss					(1,921,594)	(1,766,584)
Non-controlling interest					181,950	393,149
Additional paid-in capital					25,053,616	23,777,647
Right-of-use asset					6,961
Lease liability					$ 6,961
Adopted ASU 2016-02 [Member]
Right-of-use asset								$ 27,841
Lease liability								$ 27,841
April 30, 2020 [Member]
Non-controlling interest, description					The joint venture with GEN2 was reorganized. GEN2 shareholders exchanged their common shares in GEN2, and the individual exchanged his membership interests in NEO, for common shares representing 49% ownership in PSI. The Company retained its common shares in PSI, which provides the Company a 51% economic interest in the PSI technology and products developed by the joint venture. During year ended September 30, 2020, the entities recorded a combined loss of $333,809 relating to its operations, of which $163,556 was allocated to the non-controlling interest.
Operating loss					$ 333,809
Non-controlling interest					163,556
Repayment from investment					975,000
Distributable cash					300,000
NEO [Member]
Additional funding			$ 700,000
GEN2 [Member]
Investments to others					$ 975,000	$ 925,000
Joint venture percentage							39.00%
Employees and Consultants [Member]
Additional units reserved for issuance				13.50%
Individual [Member]
Joint venture percentage					10.00%		51.00%
Protec Scientific, Inc. [Member]
Additional funding					$ 120,000
Operating loss					172,174
Non-controlling interest					45,600
Additional paid-in capital					74,400
Acquisition description		In May 2020, the Company’s subsidiary, PSI, agreed to become a majority shareholder in Protec Scientific, Inc. (“Protec”), a company formed in April 2020 by John Yorke for the purpose of designing, developing and marketing products that use spectral photonic emissions across a variety of applications. As of September 30, 2020, PSI had advanced $191,000 to Protec in furtherance of its agreement to acquire approximately 62% of Protec, with the Company’s share being approximately 32%, based on its PSI ownership.
Loss allocated to the non-controlling interests					$ 117,732
Psoria-Shield, Inc [Member]
Ownership percentage					50.50%
Proceeds from investment					$ 750,000
Additional paid-in capital					$ 191,000
Gen 2 Funding, Inc [Member]
Ownership percentage					36.00%
Stock Option [Member]
Antidilutive securities excluded from computation of earnings per share					14,127,738	15,237,738
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share					67,634,049	66,484,049

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details)	12 Months Ended
	Sep. 30, 2020		Sep. 30, 2019
State or other jurisdiction of incorporation or organization	Nevada
Psoria-Shield, Inc [Member]
Name of consolidated subsidiary or entity	Psoria-Shield Inc. ("PSI")
State or other jurisdiction of incorporation or organization	The State of Florida
Month and Year of incorporation or formation	2009-06
Month and Year of acquisition/disposition	2012-08
Attributable interest	51.00%	[1]	100.00%
StealthCo, Inc. [Member]
Name of consolidated subsidiary or entity	StealthCo, Inc. ("StealthCo")
State or other jurisdiction of incorporation or organization	The State of Illinois
Month and Year of incorporation or formation	2014-03
Attributable interest	100.00%		100.00%
Psoria Development Company LLC. [Member]
Name of consolidated subsidiary or entity	Psoria Development Company LLC. ("PDC")
State or other jurisdiction of incorporation or organization	The State of Illinois
Month and Year of incorporation or formation	2015-01
Month and Year of acquisition/disposition	2018-11
Attributable interest	0.00%		0.00%
NEO Phototherapy, LLC, [Member]
Name of consolidated subsidiary or entity	NEO Phototherapy LLC ("NEO")
State or other jurisdiction of incorporation or organization	The State of Illinois
Month and Year of incorporation or formation	2018-12
Attributable interest	0.00%		51.00%	[1]
Protec Scientific, Inc [Member]
Name of consolidated subsidiary or entity	Protec Scientific, Inc ("Protec")
State or other jurisdiction of incorporation or organization	The State of New York
Month and Year of incorporation or formation	2020-04
Attributable interest	38.00%		0.00%
[1]	Effective April 30, 2020, the Company's 51% interest in NEO was converted into a 51% interest in PSI.

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details) (Parenthetical)	Sep. 30, 2020		Sep. 30, 2019
Psoria-Shield, Inc [Member]
Attributable interest	51.00%	[1]	100.00%
NEO Phototherapy, LLC, [Member]
Attributable interest	0.00%		51.00%	[1]
[1]	Effective April 30, 2020, the Company's 51% interest in NEO was converted into a 51% interest in PSI.

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)	12 Months Ended
	Sep. 30, 2020
Computer Equipment [Member]
Estimated useful lives of property and equipment	5 years
Medical Equipment [Member]
Estimated useful lives of property and equipment	5 years
Furniture and Fixtures [Member]
Estimated useful lives of property and equipment	7 years
Vehicles [Member]
Estimated useful lives of property and equipment	3 years
Software [Member]
Estimated useful lives of property and equipment	3 years

Loans Payable from Officers a_2

Loans Payable from Officers and Shareholders (Details Narrative)	12 Months Ended
	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)$ / shares	Sep. 30, 2018USD ($)
Loans payable from officers and shareholders		$ 399,250	$ 66,000
Due to officers and shareholders		358,250
Repaid debt		$ 25,000
Warrants exercise price | $ / shares		$ 0.15
Loans payable to related parties	$ 369,250
Stock Price [Member]
Warrant measurement input | $ / shares	0.04
Volatility [Member]
Warrant measurement input	187
Risk-free Rates [Member]
Warrant measurement input	0.20
One of the Loan Holders [Member]
Debt instrument converted amount	$ 30,000
Debt instrument converted shares | shares	575,000
Number of warrant to purchase of common stock | shares	1,150,000
Warrants exercise price | $ / shares	$ 0.07
Warrant term	5 years
Officers and Shareholders [Member]
Fair value of warrants	$ 43,815
Loans payable to related parties	1,165,250
Calvin O Harrow [Member]
Loans payable to related parties	590,250
Roy Harsch [Member]
Loans payable to related parties	205,000
William Kingsford [Member]
Loans payable to related parties	201,000
Paul Jones [Member]
Loans payable to related parties	100,000
Douglas Samuelson [Member]
Loans payable to related parties	40,000
Tom Scott [Member]
Loans payable to related parties	20,000
Psoria-Shield Inc [Member]
Loans payable from officers and shareholders	$ 796,000

U.S. Small Business Administr_2

U.S. Small Business Administration Loan Payable (Details)	12 Months Ended
	Sep. 30, 2020USD ($)
U.s. Small Business Administration Loan Payable
Debt instrument, face amount	$ 37,166
Debt interest rate	1.00%
Debt maturity date	Apr. 23, 2022
Debt maturity description	Beginning in October 2020, PSI is required to make monthly interest payments and all principal and unpaid interest is due in April 2022.

Convertible Note Agreements (De

Convertible Note Agreements (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Jul. 31, 2018	Mar. 31, 2018	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2018
Debt instrument, face amount			$ 37,166
Debt maturity date			Apr. 23, 2022
Amortization of debt discount				$ 72,078
Convertible Note Payable Agreement [Member]
Debt maturity date				Jan. 31, 2019
Debt discount					$ 3,837
Convertible Note Payable Agreement [Member] | Individual [Member]
Debt instrument, face amount		$ 165,000
Debt maturity date		Oct. 31, 2018
Debt discount		$ 165,000
Conversion of stock, shares converted				744,732
Financing cost				$ 51,434
Conversion of debt into common stock				165,000
Accrued interest				$ 8,783
Conversion of debt into common stock, shares				2,482,441
Amortization of debt discount				$ 3,837
Convertible Note Payable Agreement [Member] | Individual [Member] | Maximum [Member]
Conversion price				$ 0.10
Convertible Note Payable Agreement [Member] | Individual [Member] | Minimum [Member]
Conversion price				$ 0.07
Convertible Note Payable Agreement One [Member]
Financing cost				$ 108,630
Accrued interest				$ 6,389
Convertible Note Payable Agreement One [Member] | Individual [Member]
Debt instrument, face amount	$ 110,000
Debt maturity date	Feb. 28, 2019
Debt discount	$ 110,000				$ 68,241
Conversion of stock, shares converted				1,551,854
Conversion of debt into common stock				$ 110,000
Conversion of debt into common stock, shares				2,327,781
Amortization of debt discount				$ 68,241
Convertible Note Payable Agreement One [Member] | Individual [Member] | Maximum [Member]
Conversion price				$ 0.15
Convertible Note Payable Agreement One [Member] | Individual [Member] | Minimum [Member]
Conversion price				$ 0.05

Lease Liabilities (Details Narr

Lease Liabilities (Details Narrative) - USD ($)	Jun. 29, 2020	Feb. 28, 2019	Sep. 30, 2020	Sep. 30, 2019
Lease term		24 months
Payment for lease liability		$ 1,800	$ 20,880
Lease expiration date		Jan. 31, 2021	Feb. 28, 2024
Right of use assets		$ 27,841	$ 6,961
Lease, discount rate		4.00%
Lease liability			6,961
Lease rent expense			21,600
Amortization of right of use asset			20,880
Monthly lease payment			11,000
Lease obligation remaining			631,587
Security deposit relating to the lease				$ 15,000
Operating lease obligation			$ 438,296
Operating lease, description			Commencing on October 1, 2016, the Company's wholly-owned subsidiary, StealthCo, entered into a non-cancellable lease agreement to lease its office facilities in Oak Ridge, Tennessee. The term of the lease is five years and expires September 30, 2021. On January 6, 2020, the Company entered into an agreement with the owners to terminate the agreement effective January 1, 2020. Under the agreement, the Company agreed to pay $11,000 and abandon certain Company property as documented in the agreement. During the year ended September 30, 2020, the $11,000 was paid by the Company.
Hanover Hoffman Estates LLC [Member]
Rent base	$ 672,878		$ 672,888

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - USD ($)	Jan. 02, 2020	Apr. 30, 2020	Mar. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	May 28, 2020	Sep. 03, 2019	Sep. 02, 2019	Jan. 02, 2018	Dec. 29, 2017
Common stock, shares authorized				200,000,000	200,000,000		200,000,000	185,000,000
Common stock, shares issued				118,252,077	107,497,077
Common stock, shares outstanding				118,252,077	107,497,077
Common stock issued for cash					$ 10,000
Warrant exercise price					$ 0.15
Number of stock issued for service, amount					$ 79,029
Number of vested shares				2,775,000
Number options to purchase of common stock				5,000,000	250,000
Options exercisable term				3 years 7 months 10 days
Number of cancellation of stock options to purchase				3,360,000
Aggregate intrinsic value for option shares				$ 184,375
Closing stock price						$ 0.03
Volatility rate				183.00%
Risk-free interest rate				0.34%
Incremental fair value of warrants from modification				$ 22,680
Unvested compensation				96,764
Stock Option [Member]
Stock based compensation				$ 263,414	$ 300,925
Conversion of Loan Payable [Member]
Number of warrants issued to purchase common shares				1,150,000
Warrant term				5 years
Warrant exercise price				$ 0.07
Fair value of warrants				$ 43,815
Minimum [Member]
Stock options exercise price				$ 0.14
Volatility rate				157.60%	126.80%
Risk-free interest rate				0.17%	1.60%
Maximum [Member]
Stock options exercise price				$ 0.30
Volatility rate				197.00%	144.00%
Risk-free interest rate				1.60%	2.47%
2010 Non-Qualified Stock Option Plan [Member]
Common stock, shares authorized									30,000,000	7,500,000
Vest Monthly from April 2020 Through March 2021 [Member]
Number of vested shares		1,800,000
Vest Monthly from April 2020 Through March 2023 [Member]
Number of vested shares		11,250,000
Vest Over Time [Member]
Number of vested shares		13,050,000
Vest in April 2020 Through March 2021 [Member]
Number of cancellation of stock options to purchase				1,550,000
Stock options exercise price				$ 0.14
Board of Directors [Member]
Number of restricted shares issued during period, shares		20,170,000
Number of vested shares		7,120,000
Board of Directors [Member] | Stock Warrants [Member]
Number of stock warrants approved for extension	66,000,000
Stock warrants extension, description	The Company's Board of Directors approved the extension of the Company's unexpired stock warrants as of December 31, 2019, by an additional one year period. This change affected approximately 66,000,000 warrant shares including approximately 20,000,000 warrant shares that were set to expire by the year ending September 30, 2020. The 66,000,000 warrant shares had exercise prices ranging from $0.12 per share to $0.40 per share.
Board of Directors [Member] | Stock Warrants [Member]
Fair value of warrants				$ 507,265
Board of Directors [Member] | Minimum [Member] | Stock Warrants [Member]
Warrant exercise price	$ 0.12
Board of Directors [Member] | Maximum [Member] | Stock Warrants [Member]
Warrant exercise price	$ 0.40
Employee [Member]
Number options to purchase of common stock					250,000
Fair value of stock options					$ 10,366
Options exercisable term					5 years
Stock based compensation					$ 10,366
Employee [Member] | Minimum [Member]
Stock option exercise price per share					$ 0.03
Employee [Member] | Maximum [Member]
Stock option exercise price per share					$ 0.06
CEO [Member]
Number of vested shares				1,125,000
Fair value of stock options				$ 127,500
Stock option exercise price per share				$ 0.04
Number of options to purchase common stock, shares				4,250,000
Number of options re-priced during the period			1,200,000
Stock option repricing, description			Repricing of stock options to purchase 1,200,000 shares with an exercise price of $0.14 per share to $0.04 per share that had vested as of March 31, 2020,
CEO [Member] | Vest Monthly from April 2020 Through March 2021 [Member]
Number of options re-priced during the period			600,000
Stock option repricing, description			Repricing of stock options to purchase 600,000 shares with an exercise price of $0.14 per share to $0.04 per share that were set to vest monthly from April 2020 through March 2021.
CEO [Member] | Vest Monthly from October 2020 Through March 2023 [Member]
Number of vested shares				3,125,000
Several Employee [Member]
Number options to purchase of common stock				750,000
Fair value of stock options				$ 59,376
Options exercisable term				5 years
Several Employee [Member] | Minimum [Member]
Stock option exercise price per share				$ 0.04
Several Employee [Member] | Maximum [Member]
Stock option exercise price per share				$ 0.09
Common Stock [Member]
Common stock issued for cash					$ 143
Common stock issued for cash, shares					142,857
Number of stock issued for service					1,277,143
Number of stock issued for service, amount					$ 1,277
Common Stock [Member] | PSI Consultants [Member]
Number of stock issued for service				285,000
Number of stock issued for service, amount				$ 22,800
Warrant [Member]
Number of warrants issued to purchase common shares					284,714
Warrant term					5 years
Warrant exercise price					$ 0.15
Options exercisable term				1 year 10 months 6 days

Shareholders' Equity - Summary

Shareholders' Equity - Summary of Restricted Common Stock (Details)	12 Months Ended
	Sep. 30, 2020USD ($)$ / sharesshares
Equity [Abstract]
Number of Restricted Shares Non-vested, Beginning balance | shares
Number of Restricted Shares Non-vested, Granted | shares	20,170,000
Number of Restricted Shares Non-vested, Vested | shares	(9,895,000)
Number of Restricted Shares Non-vested, Forfeited | shares
Number of Restricted Shares Non-vested, Ending balance | shares	10,275,000
Fair Value Non-vested, Beginning balance | $
Fair Value Non-vested, Granted | $	605,100
Fair Value Non-vested, Vested | $	(296,850)
Fair Value Non-vested, Forfeited | $
Fair Value Non-vested, Ending balance | $	$ 308,250
Weighted Average Grant Date Fair Value Non-vested, Beginning balance | $ / shares
Weighted Average Grant Date Fair Value Non-vested, Granted | $ / shares	0.03
Weighted Average Grant Date Fair Value Non-vested, Vested | $ / shares	0.03
Weighted Average Grant Date Fair Value Non-vested, Forfeited | $ / shares
Weighted Average Grant Date Fair Value Non-vested, Ending balance | $ / shares	$ 0.03

Shareholders' Equity - Schedule

Shareholders' Equity - Schedule of Stock Option Activity (Details) - $ / shares	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Number of Option Shares Outstanding, Number, Beginning Balance	15,237,738	17,946,667
Number of Option Shares Outstanding, Granted	5,000,000	250,000
Number of Option Shares Outstanding, Cancelled	(4,910,000)	(646,429)
Number of Option Shares Outstanding, Exercised
Number of Option Shares Outstanding, Expired	(1,200,000)	(212,500)
Number of Option Shares Outstanding, Number, Ending Balance	14,127,738	15,237,738
Number of Option Shares Outstanding, Vested and exercisable, Ending Balance	10,702,738
Number of Option Shares Outstanding, Unvested, Ending Balance	3,425,500
Weighted Average Exercise Price, Number, Beginning Balance	$ 0.28	$ 0.28
Weighted Average Exercise Price, Granted	0.05	0.05
Weighted Average Exercise Price, Cancelled	0.14	0.17
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired	0.15	0.37
Weighted Average Exercise Price, Number, Ending Balance	0.23	0.28
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	0.29
Weighted Average Exercise Price, Unvested, Ending Balance	0.04
Minimum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	0.03	0.10
Weighted Average Exercise Price, Granted	0.04	0.03
Weighted Average Exercise Price, Cancelled	0.14	0.14
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired	0.11	0.13
Weighted Average Exercise Price, Number, Ending Balance	0.03	0.03
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	0.03
Maximum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	2	2
Weighted Average Exercise Price, Granted	0.09	0.06
Weighted Average Exercise Price, Cancelled	0.30	0.19
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired	0.25	0.40
Weighted Average Exercise Price, Number, Ending Balance	2	$ 2
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	$ 2

Shareholders' Equity - Schedu_2

Shareholders' Equity - Schedule of Outstanding and Exercisable Options by Exercise Price Range (Details) - $ / shares	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2018
Range of Exercise Prices, Lower Limit	$ 0.06
Range of Exercise Prices, Upper Limit	$ 2
Number of Options, Outstanding, Number	14,127,738	15,237,738	17,946,667
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	3 years 18 days
Number of Options, Outstanding, Weighted Average Exercise Price	$ 0.23	$ 0.28	$ 0.28
Number of Options, Exercisable, Number	10,702,738
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	3 years 7 months 10 days
Number of Options, Exercisable, Weighted Average Exercise Price	$ 0.29
Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit	0.03
Range of Exercise Prices, Upper Limit	$ 0.39
Number of Options, Outstanding, Number	12,665,238
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	5 years 6 months 14 days
Number of Options, Outstanding, Weighted Average Exercise Price	$ 0.09
Number of Options, Exercisable, Number	9,240,238
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	4 years 1 month 20 days
Number of Options, Exercisable, Weighted Average Exercise Price	$ 0.11
Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit	0.40
Range of Exercise Prices, Upper Limit	$ 0.99
Number of Options, Outstanding, Number	62,500
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	1 year 6 months
Number of Options, Outstanding, Weighted Average Exercise Price	$ 0.40
Number of Options, Exercisable, Number	62,500
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	1 year 6 months
Number of Options, Exercisable, Weighted Average Exercise Price	$ 0.40
Exercise Price Range Three [Member]
Range of Exercise Prices, Lower Limit	1
Range of Exercise Prices, Upper Limit	$ 1.99
Number of Options, Outstanding, Number	750,000
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	2 months 30 days
Number of Options, Outstanding, Weighted Average Exercise Price	$ 1
Number of Options, Exercisable, Number	750,000
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	2 months 30 days
Number of Options, Exercisable, Weighted Average Exercise Price	$ 1
Exercise Price Range Four [Member]
Range of Exercise Prices, Upper Limit	$ 2
Number of Options, Outstanding, Number	650,000
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	2 months 30 days
Number of Options, Outstanding, Weighted Average Exercise Price	$ 2
Number of Options, Exercisable, Number	650,000
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	2 months 30 days
Number of Options, Exercisable, Weighted Average Exercise Price	$ 2

Shareholders' Equity - Schedu_3

Shareholders' Equity - Schedule of Assumptions Used for Options Granted (Details) - $ / shares	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Expected dividends
Expected volatility	183.00%
Risk free interest rate	0.34%
Expected life of options	2 years 6 months	2 years 6 months
Minimum [Member]
Exercise price	$ 0.04	$ 0.03
Expected volatility	157.60%	126.80%
Risk free interest rate	0.17%	1.60%
Maximum [Member]
Exercise price	$ 0.09	$ 0.06
Expected volatility	197.00%	144.00%
Risk free interest rate	1.60%	2.47%

Shareholders' Equity - Schedu_4

Shareholders' Equity - Schedule of Warrant Activity (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Number of Warrant Shares Outstanding, Number, Beginning Balance	66,484,049	67,907,728
Number of Warrant Shares Outstanding, Granted	1,150,000	284,714
Number of Warrant Shares Outstanding, Cancelled
Number of Warrant Shares Outstanding, Exercised
Number of Warrant Shares Outstanding, Expired		(1,708,393)
Number of Warrant Shares Outstanding, Number, Ending Balance	67,634,049	66,484,049
Number of Warrant Shares Outstanding, Vested and exercisable, Ending Balance	67,634,049
Weighted Average Exercise Price, Number, Beginning Balance	$ 0.17	$ 0.17
Weighted Average Exercise Price, Granted	0.07	0.15
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired		0.44
Weighted Average Exercise Price, Number, Ending Balance	0.16	0.17
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	0.16
Minimum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	0.12	0.12
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired		0.30
Weighted Average Exercise Price, Number, Ending Balance	0.07	0.12
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	0.07
Maximum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	0.40	1
Weighted Average Exercise Price, Granted	0.07	0.15
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired		0.67
Weighted Average Exercise Price, Number, Ending Balance	0.40	$ 0.40
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	$ 0.40

Shareholders' Equity - Schedu_5

Shareholders' Equity - Schedule of Outstanding and Exercisable Warrants by Exercise Price Range (Details) - $ / shares	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2018
Range of Exercise Prices, Lower Limit	$ 0.06
Range of Exercise Prices, Upper Limit	$ 2
Number of Warrants, Outstanding, Number	14,127,738	15,237,738	17,946,667
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	3 years 18 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.23	$ 0.28	$ 0.28
Number of Warrants, Exercisable, Number	10,702,738
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	3 years 7 months 10 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.29
Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit	0.03
Range of Exercise Prices, Upper Limit	$ 0.39
Number of Warrants, Outstanding, Number	12,665,238
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	5 years 6 months 14 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.09
Number of Warrants, Exercisable, Number	9,240,238
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	4 years 1 month 20 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.11
Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit	0.40
Range of Exercise Prices, Upper Limit	$ 0.99
Number of Warrants, Outstanding, Number	62,500
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	1 year 6 months
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.40
Number of Warrants, Exercisable, Number	62,500
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	1 year 6 months
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.40
Warrant [Member]
Range of Exercise Prices, Lower Limit	0.12
Range of Exercise Prices, Upper Limit	$ 0.40
Number of Warrants, Outstanding, Number	67,634,049
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	1 year 10 months 6 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.16
Number of Warrants, Exercisable, Number	67,634,049
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	1 year 10 months 6 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.16
Warrant [Member] | Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit	0.12
Range of Exercise Prices, Upper Limit	$ 0.20
Number of Warrants, Outstanding, Number	60,429,384
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	1 year 11 months 19 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.15
Number of Warrants, Exercisable, Number	60,429,384
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	1 year 11 months 19 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.15
Warrant [Member] | Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit	0.21
Range of Exercise Prices, Upper Limit	$ 0.40
Number of Warrants, Outstanding, Number	7,204,665
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	10 months 17 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.26
Number of Warrants, Exercisable, Number	7,204,665
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	10 months 17 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.26

Segment Reporting - Schedule of

Segment Reporting - Schedule of Assets of Reportable Segments (Details) - USD ($)	Sep. 30, 2020	Sep. 30, 2019	Feb. 28, 2019
Cash	$ 51,320	$ 53,147
Inventories	94,560
Prepaid expenses and other current assets	500	55,000
Total current assets	146,380	108,147
Right-of-use asset	6,961		$ 27,841
Total other assets	6,961	1,562
TOTAL ASSETS	153,341	$ 109,709
Corporate [Member]
Cash	1,079
Inventories
Prepaid expenses and other current assets	500
Total current assets	1,579
Right-of-use asset
Total other assets
TOTAL ASSETS	1,579
Medical Devices [Member]
Cash	44,444
Inventories	94,560
Prepaid expenses and other current assets
Total current assets	139,004
Right-of-use asset	6,961
Total other assets	6,961
TOTAL ASSETS	145,965
Authentication and Encryption [Member]
Cash	5,797
Inventories
Prepaid expenses and other current assets
Total current assets	5,797
Right-of-use asset
Total other assets
TOTAL ASSETS	$ 5,797

Segment Reporting - Schedule _2

Segment Reporting - Schedule of Operations of Reportable Segments (Details) - USD ($)	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Total Sales	$ 5,000	$ 33,375
Cost of goods sold		20,025
Gross profit	5,000	13,350
Operating expenses	1,926,594	1,779,934
Loss from operations	(1,921,594)	(1,766,584)
Trade [Member]
Total Sales	5,000	19,508
Consulting Services [Member]
Total Sales		13,867
Corporate [Member]
Total Sales
Cost of goods sold
Gross profit
Operating expenses	1,004,477	782,961
Loss from operations	(1,004,477)	(782,961)
Corporate [Member] | Trade [Member]
Total Sales
Corporate [Member] | Consulting Services [Member]
Total Sales
Medical Devices [Member]
Total Sales
Cost of goods sold
Gross profit
Operating expenses	852,542	641,236
Loss from operations	(852,542)	(641,236)
Medical Devices [Member] | Trade [Member]
Total Sales
Medical Devices [Member] | Consulting Services [Member]
Total Sales
Authentication and Encryption [Member]
Total Sales	5,000	33,375
Cost of goods sold		20,025
Gross profit	5,000	13,350
Operating expenses	69,575	355,737
Loss from operations	(64,575)	(342,387)
Authentication and Encryption [Member] | Trade [Member]
Total Sales	5,000	19,508
Authentication and Encryption [Member] | Consulting Services [Member]
Total Sales		$ 13,867

Legal Matters (Details Narrativ

Legal Matters (Details Narrative) - USD ($)	Jun. 29, 2020	Sep. 30, 2020
Interest rate of negotiated settlement		4.00%
Hanover Hoffman Estates, LLC [Member]
Rent base	$ 672,878	$ 672,888
Ex- Employee [Member]
Claims amount		$ 21,600
Wages increase rate		2.00%
Former CEO [Member]
Claims amount		$ 179,548
Wages increase rate		2.00%
Claim alleges unpaid wages		$ 158,715
Unpaid vacation amount		20,833
Amount earn throught on disclosure trading		$ 130,000

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Sep. 30, 2020USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carryforwards for federal income tax	$ 20,000,000
Operating loss carryforwards expiration year	Future taxable income through 2040
Net loss carryforwards valuation allowance	$ 5,000,000

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income tax benefit at federal statutory rate	(21.00%)	(21.00%)
State income tax benefit, net of federal benefit	(4.00%)	(4.00%)
Change in valuation allowance	25.00%	25.00%
Income taxes at effective income tax rate

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 5,117,750	$ 4,657,556
Less: Valuation allowance	(5,117,750)	(4,657,556)
Net deferred tax assets

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Feb. 05, 2021	Sep. 30, 2020
Loans payable to related parties		$ 369,250
Calvin O Harrow [Member]
Loans payable to related parties		590,250
Roy Harsch [Member]
Loans payable to related parties		205,000
William Kingsford [Member]
Loans payable to related parties		201,000
Paul Jones [Member]
Loans payable to related parties		100,000
Douglas Samuelson [Member]
Loans payable to related parties		$ 40,000
Subsequent Event [Member]
Loans payable to related parties	$ 375,000
Subsequent Event [Member] | Calvin O Harrow [Member]
Loans payable to related parties	745,250
Subsequent Event [Member] | Roy Harsch [Member]
Loans payable to related parties	235,000
Subsequent Event [Member] | William Kingsford [Member]
Loans payable to related parties	291,000
Subsequent Event [Member] | Paul Jones [Member]
Loans payable to related parties	100,000
Subsequent Event [Member] | Douglas Samuelson [Member]
Loans payable to related parties	40,000
Subsequent Event [Member] | Thomas Scott [Member]
Loans payable to related parties	$ 20,000